LOGIN  |  REGISTER
C4 Therapeutics

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 133.73
1.08 0.81
4.05M
1.74B
US$ 232.690B
US$ 479.46
-11.95 -2.43
1.31M
377.61M
US$ 181.050B
US$ 449.68
-6.17 -1.35
2.05M
358.48M
US$ 161.200B
US$ 102.71
-1.63 -1.56
8.55M
1.48B
US$ 152.010B
US$ 383.34
-5.45 -1.40
967,388
382.31M
US$ 146.550B
US$ 190.03
-5.13 -2.63
3.82M
716.05M
US$ 136.070B
US$ 94.03
-0.22 -0.23
5.18M
1.28B
US$ 120.360B
US$ 711.42
-8.38 -1.16
512,098
124.38M
US$ 88.490B
US$ 186.84
-3.72 -1.95
1.04M
286.63M
US$ 53.550B
US$ 641.14
-4.02 -0.62
323,483
80.00M
US$ 51.290B
US$ 77.57
-0.44 -0.56
4.35M
587.10M
US$ 45.540B
US$ 270.14
-4.47 -1.63
876,376
146.42M
US$ 39.550B
US$ 78.29
-1.39 -1.74
1.24M
494.40M
US$ 38.710B
US$ 152.24
-0.23 -0.15
1.07M
238.79M
US$ 36.350B
US$ 123.24
-3.49 -2.75
1.41M
283.50M
US$ 34.940B
US$ 187.22
-3.47 -1.82
936,499
170.00M
US$ 31.830B
US$ 76.22
0.22 0.29
3.03M
392.16M
US$ 29.890B
US$ 1.00
-23.18 -1.81
107,809
20.60M
US$ 25.950B
US$ 249.88
-2.55 -1.01
642,266
98.49M
US$ 24.610B
US$ 341.78
3.84 1.14
521,556
70.39M
US$ 24.060B
US$ 168.51
-5.30 -3.05
908,364
137.25M
US$ 23.130B
US$ 277.95
-1.77 -0.63
340,549
83.10M
US$ 23.100B
US$ 182.91
-0.55 -0.30
436,760
111.82M
US$ 20.450B
US$ 103.08
-1.18 -1.13
868,943
198.10M
US$ 20.420B
US$ 253.50
-10.24 -3.88
711,791
71.91M
US$ 18.230B
US$ 295.39
-7.25 -2.40
320,798
59.52M
US$ 17.580B
US$ 37.78
-0.73 -1.90
993,060
434.29M
US$ 16.410B
US$ 95.12
-4.19 -4.22
1.59M
158.30M
US$ 15.060B
US$ 86.40
-2.38 -2.68
8.76M
168.68M
US$ 14.570B
US$ 64.45
-1.93 -2.91
1.01M
222.42M
US$ 14.330B
US$ 490.64
-7.15 -1.44
371,593
28.09M
US$ 13.780B
US$ 175.00
0.20 0.11
1.72M
77.77M
US$ 13.610B
US$ 66.68
-1.78 -2.60
2.65M
198.81M
US$ 13.260B
US$ 23.99
-0.50 -2.04
5.05M
513.62M
US$ 12.320B
US$ 272.73
-3.65 -1.32
387,354
39.00M
US$ 10.640B
US$ 53.94
-2.06 -3.68
2.23M
189.32M
US$ 10.210B
US$ 45.28
-0.78 -1.69
837,736
216.83M
US$ 9.820B
US$ 82.87
-2.81 -3.28
959,440
116.07M
US$ 9.620B
US$ 147.44
1.23 0.84
721,517
54.32M
US$ 8.010B
US$ 152.89
-6.85 -4.29
444,867
49.21M
US$ 7.520B
US$ 54.90
-1.90 -3.35
2.85M
124.71M
US$ 6.850B
US$ 58.74
-0.88 -1.48
667,200
112.63M
US$ 6.620B
US$ 113.54
-5.97 -5.00
747,393
56.26M
US$ 6.390B
US$ 280.34
-5.56 -1.94
209,422
21.99M
US$ 6.160B
US$ 179.82
-1.21 -0.67
231,630
32.13M
US$ 5.780B
US$ 130.31
-2.19 -1.65
611,526
44.19M
US$ 5.760B
US$ 74.01
0.28 0.38
677,238
76.92M
US$ 5.690B
US$ 15.19
-0.13 -0.85
308,821
353.87M
US$ 5.380B
US$ 85.53
-4.68 -5.19
693,464
59.22M
US$ 5.070B
US$ 82.76
-4.71 -5.38
868,238
57.35M
US$ 4.750B
US$ 30.91
-1.16 -3.62
3.04M
151.72M
US$ 4.690B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 16.05
-0.07 -0.43
2.17M
284.05M
US$ 4.560B
US$ 114.57
-2.42 -2.07
841,398
34.09M
US$ 3.910B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 52.94
-2.05 -3.73
877,006
67.99M
US$ 3.600B
US$ 101.34
-2.89 -2.77
382,719
35.03M
US$ 3.550B
US$ 130.38
-4.65 -3.44
238,709
24.69M
US$ 3.220B
US$ 63.25
-1.77 -2.72
555,496
49.21M
US$ 3.110B
US$ 56.22
-1.12 -1.95
582,708
54.60M
US$ 3.070B
US$ 26.75
-0.80 -2.90
1.36M
105.19M
US$ 2.810B
US$ 52.20
-1.17 -2.19
1.45M
48.18M
US$ 2.510B
US$ 80.05
-2.75 -3.32
721,359
29.57M
US$ 2.370B
US$ 15.26
-0.37 -2.37
1.64M
147.98M
US$ 2.260B
US$ 92.29
-1.94 -2.06
75,599
22.64M
US$ 2.090B
US$ 37.14
-1.50 -3.88
1.13M
55.64M
US$ 2.070B
US$ 28.57
-1.37 -4.58
1.16M
67.90M
US$ 1.940B
US$ 40.70
-1.60 -3.78
363,724
47.18M
US$ 1.920B
US$ 35.07
-2.49 -6.63
700,876
49.70M
US$ 1.740B
US$ 52.90
-1.15 -2.13
156,812
30.96M
US$ 1.640B
US$ 25.31
-0.30 -1.17
1.66M
60.36M
US$ 1.530B
US$ 27.70
-0.38 -1.35
392,330
49.55M
US$ 1.370B
US$ 38.04
-0.61 -1.58
581,128
36.05M
US$ 1.370B
US$ 29.66
-1.54 -4.94
445,437
45.84M
US$ 1.360B
US$ 12.15
-0.58 -4.56
765,705
111.80M
US$ 1.360B
US$ 26.43
-0.57 -2.11
488,180
49.69M
US$ 1.310B
US$ 9.29
-0.24 -2.52
811,670
135.30M
US$ 1.260B
US$ 25.51
-1.22 -4.56
553,291
47.91M
US$ 1.220B
US$ 5.50
-0.27 -4.68
4.03M
217.20M
US$ 1.190B
US$ 15.06
-0.41 -2.65
839,465
77.91M
US$ 1.170B
US$ 1.40
-0.03 -2.10
1.37M
793.78M
US$ 1.110B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 37.47
-0.34 -0.90
313,811
28.97M
US$ 1.090B
US$ 6.94
-0.20 -2.80
433,285
147.96M
US$ 1.030B
US$ 7.96
-0.38 -4.56
2.00M
129.18M
US$ 1.030B
US$ 14.52
-0.58 -3.84
469,409
67.30M
US$ 977.200M
US$ 14.83
-0.51 -3.32
745,737
63.21M
US$ 937.400M
US$ 71.27
-3.00 -4.04
40,030
12.72M
US$ 906.550M
US$ 12.27
-0.52 -4.07
2.22M
67.57M
US$ 829.080M
US$ 16.41
-0.39 -2.32
818,377
46.01M
US$ 755.020M
US$ 13.53
0.00 0.00
871,242
53.23M
US$ 720.200M
US$ 15.70
-0.62 -3.80
522,186
43.14M
US$ 677.300M
US$ 7.24
-0.44 -5.73
1.78M
93.04M
US$ 673.610M
US$ 21.88
-0.37 -1.66
183,471
30.61M
US$ 669.750M
US$ 21.42
-1.33 -5.85
293,390
29.01M
US$ 621.390M
US$ 14.91
-0.09 -0.60
520,406
39.49M
US$ 588.800M
US$ 12.22
-0.19 -1.53
395,403
46.40M
US$ 567.010M
US$ 18.87
-0.01 -0.05
154,522
28.21M
US$ 532.320M
US$ 3.94
-0.20 -4.83
1.08M
127.22M
US$ 501.250M
US$ 5.20
-0.04 -0.76
749,380
95.94M
US$ 498.890M
US$ 15.73
0.73 4.87
139,064
31.66M
US$ 498.010M
US$ 1.29
-0.04 -3.01
1.08M
382.00M
US$ 492.780M
US$ 19.65
-0.68 -3.34
134,444
25.07M
US$ 492.630M
C$ 1.70
0.00 0.00
160,684
285.82M
C$ 485.890M
US$ 7.23
-0.05 -0.69
316,107
66.89M
US$ 483.610M
US$ 11.30
-0.20 -1.74
254,548
41.52M
US$ 469.180M
US$ 31.96
-0.27 -0.84
89,730
14.30M
US$ 457.030M
US$ 7.22
-0.22 -2.96
316,523
63.17M
US$ 456.090M
US$ 10.65
-0.32 -2.92
618,746
40.63M
US$ 432.710M
US$ 29.19
0.65 2.28
505,253
14.80M
US$ 432.010M
US$ 11.57
0.03 0.26
304,053
35.82M
US$ 414.440M
US$ 5.34
-0.13 -2.38
1.20M
77.24M
US$ 412.460M
US$ 9.31
-0.11 -1.17
743,117
40.92M
US$ 380.970M
US$ 10.84
-0.29 -2.61
766,093
34.98M
US$ 379.180M
US$ 0.46
0.0047 1.03
5.27M
814.68M
US$ 374.750M
US$ 16.01
-0.19 -1.17
79,055
23.06M
US$ 369.190M
US$ 1.18
-0.08 -6.35
10.28M
300.37M
US$ 354.440M
US$ 1.57
0.02 1.29
2.13M
225.31M
US$ 353.740M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 9.86
-0.14 -1.40
145,024
33.08M
US$ 326.170M
US$ 33.96
-1.32 -3.74
30,500
8.90M
US$ 302.240M
US$ 13.51
-0.20 -1.46
164,503
22.29M
US$ 301.140M
US$ 15.77
0.07 0.45
25,842
18.90M
US$ 297.960M
US$ 6.78
-0.15 -2.16
351,640
38.79M
US$ 263.000M
US$ 2.85
-0.03 -1.04
288,558
91.07M
US$ 259.550M
US$ 3.48
0.10 2.96
1.03M
74.26M
US$ 258.420M
US$ 3.91
-0.07 -1.64
867,727
63.94M
US$ 249.690M
US$ 13.69
-0.43 -3.05
91,908
17.77M
US$ 243.270M
US$ 3.31
-0.01 -0.30
310,553
73.14M
US$ 242.090M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 5.75
0.00 0.00
80,577
40.63M
US$ 233.620M
US$ 8.54
-0.02 -0.23
206,399
27.04M
US$ 230.920M
US$ 4.81
0.02 0.42
539,544
46.47M
US$ 223.520M
US$ 4.43
-0.25 -5.34
174,388
49.87M
US$ 220.920M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 1.18
-0.02 -1.67
7.80M
182.56M
US$ 215.420M
US$ 9.74
-0.23 -2.31
157,483
22.00M
US$ 214.280M
US$ 3.14
-0.32 -9.25
1.36M
66.12M
US$ 207.620M
US$ 7.87
-0.36 -4.37
137,969
26.07M
US$ 205.170M
US$ 9.97
-0.15 -1.48
191,385
20.43M
US$ 203.690M
US$ 5.60
-0.12 -2.10
354,282
36.09M
US$ 202.100M
US$ 5.57
0.57 11.40
225,324
36.06M
US$ 200.850M
US$ 62.31
-0.63 -1.00
5,604
3.21M
US$ 200.020M
US$ 23.88
-1.18 -4.71
45,702
8.35M
US$ 199.400M
US$ 4.08
0.19 4.88
5.31M
48.51M
US$ 197.920M
US$ 5.24
-0.31 -5.59
64,927
37.54M
US$ 196.710M
US$ 3.69
-0.14 -3.66
201,744
49.50M
US$ 182.660M
US$ 3.92
-0.10 -2.49
59,356
46.24M
US$ 181.260M
US$ 3.46
-0.16 -4.42
105,376
52.37M
US$ 181.200M
US$ 1.57
-0.02 -1.26
1.67M
112.68M
US$ 176.910M
US$ 1.45
-0.03 -2.03
493,073
106.61M
US$ 154.580M
US$ 12.47
0.34 2.80
59,775
11.93M
US$ 148.770M
US$ 4.56
0.18 4.11
299,966
27.02M
US$ 123.210M
US$ 4.04
0.04 1.00
64,250
30.05M
US$ 121.400M
US$ 3.03
0.10 3.24
46,245
39.71M
US$ 120.120M
C$ 1.00
0.02 2.04
63,881
119.82M
C$ 119.820M
US$ 6.95
-0.11 -1.56
58,602
17.04M
US$ 118.430M
US$ 2.69
0.01 0.37
95,325
43.44M
US$ 116.850M
US$ 10.08
1.21 13.66
267,080
11.45M
US$ 115.360M
US$ 3.10
0.03 0.98
42,674
37.09M
US$ 114.980M
US$ 33.73
-1.46 -4.15
47,341
3.26M
US$ 109.960M
US$ 1.03
-0.04 -3.74
1.63M
101.89M
US$ 104.950M
US$ 2.38
-0.04 -1.65
47,029
41.72M
US$ 99.290M
US$ 0.63
-0.04 -5.52
155,012
156.55M
US$ 99.100M
C$ 0.83
-0.03 -3.49
128,009
116.96M
C$ 97.080M
US$ 15.69
-0.01 -0.06
6,963
6.17M
US$ 96.810M
US$ 2.45
-0.16 -6.13
53,026
37.39M
US$ 91.610M
US$ 1.42
0.07 5.19
804,727
63.53M
US$ 90.210M
US$ 2.85
0.01 0.35
63,305
29.00M
US$ 82.650M
US$ 0.62
-0.0011 -0.18
44,346
130.32M
US$ 80.800M
US$ 2.10
0.10 5.00
37,753
37.82M
US$ 79.420M
US$ 8.35
-0.46 -5.22
24,260
9.03M
US$ 75.400M
US$ 1.21
0.00 0.00
48,437
59.24M
US$ 71.680M
US$ 1.70
0.01 0.59
266,278
40.75M
US$ 69.280M
US$ 0.64
0.0094 1.50
273,304
107.60M
US$ 68.540M
US$ 0.99
-0.007 -0.70
651,433
68.65M
US$ 67.690M
US$ 3.54
0.00 0.00
0
18.52M
US$ 65.560M
US$ 1.29
0.00 0.00
0
49.95M
US$ 64.440M
US$ 1.58
-0.04 -2.47
43,413
39.62M
US$ 62.600M
US$ 0.94
-0.02 -1.60
112,802
62.76M
US$ 58.870M
US$ 0.38
-0.04 -9.20
3.95M
146.63M
US$ 54.990M
US$ 3.18
-0.06 -1.85
39,762
16.44M
US$ 52.280M
US$ 1.94
-0.05 -2.51
290,815
26.73M
US$ 51.860M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
US$ 1.28
-0.03 -2.29
413,454
38.08M
US$ 48.740M
US$ 1.42
0.00 0.00
86,363
34.31M
US$ 48.720M
US$ 1.41
-0.03 -2.08
515,157
34.36M
US$ 48.450M
C$ 0.19
-0.01 -5.13
137,175
257.06M
C$ 47.560M
US$ 4.70
0.00 0.00
0
10.07M
US$ 47.330M
US$ 0.59
-0.004 -0.68
39,460
78.56M
US$ 46.040M
US$ 0.80
-0.0023 -0.29
7,508
57.00M
US$ 45.540M
US$ 4.26
0.05 1.19
32,975
10.60M
US$ 45.160M
US$ 1.48
-0.06 -3.90
76,346
30.30M
US$ 44.840M
US$ 0.89
-0.0053 -0.59
557,057
50.00M
US$ 44.450M
US$ 0.75
0.05 6.54
18.55M
55.27M
US$ 41.230M
US$ 0.09
-0.0047 -4.96
573,999
453.80M
US$ 40.840M
C$ 0.37
0.005 1.37
4,000
105.09M
C$ 38.880M
US$ 1.21
0.05 4.31
361,431
30.81M
US$ 37.280M
US$ 4.74
-0.28 -5.58
32,575
7.58M
US$ 35.930M
US$ 0.84
-0.06 -6.14
2.69M
37.80M
US$ 31.900M
US$ 19.50
-0.73 -3.61
30,743
1.62M
US$ 31.590M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 5.82
-0.06 -1.02
53,744
5.30M
US$ 30.850M
US$ 1.29
-0.04 -3.01
60,504
21.52M
US$ 27.760M
C$ 0.26
0.04 18.18
183,658
103.95M
C$ 27.030M
US$ 3.47
-0.17 -4.67
113,090
7.50M
US$ 26.020M
US$ 0.82
0.009 1.11
37,374
29.94M
US$ 24.550M
US$ 0.87
-0.01 -1.63
847,383
27.91M
US$ 24.280M
US$ 0.85
-0.02 -2.19
24,632
27.90M
US$ 23.720M
C$ 0.20
0.00 0.00
211,572
114.82M
C$ 22.960M
US$ 1.32
-0.05 -3.65
92,758
16.99M
US$ 22.430M
US$ 1.19
-0.02 -1.65
141,225
18.63M
US$ 22.170M
C$ 0.28
0.005 1.82
25,751
77.41M
C$ 21.670M
C$ 0.34
0.005 1.52
43,664
60.55M
C$ 20.280M
US$ 0.44
-0.0015 -0.34
348,558
44.53M
US$ 19.680M
C$ 0.07
0.00 0.00
237,000
301.79M
C$ 19.620M
US$ 2.42
-0.05 -2.02
27,089
8.07M
US$ 19.530M
US$ 0.71
-0.02 -2.70
2,140
26.57M
US$ 18.860M
C$ 0.11
0.005 4.76
276,610
166.00M
C$ 18.260M
US$ 3.88
-0.18 -4.43
904,526
4.68M
US$ 18.160M
US$ 7.11
0.01 0.14
65,808
2.40M
US$ 17.060M
US$ 2.15
-0.04 -1.83
33,309
7.76M
US$ 16.680M
US$ 0.31
0.00 0.00
0
52.24M
US$ 16.390M
US$ 1.79
0.06 3.47
145,011
8.98M
US$ 16.070M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 1.91
0.59 44.70
79.33M
8.21M
US$ 15.680M
US$ 0.89
0.02 2.02
131,029
17.42M
US$ 15.420M
US$ 0.78
-0.005 -0.64
823,120
19.25M
US$ 15.030M
US$ 0.46
0.04 8.24
660,953
31.90M
US$ 14.670M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
US$ 0.34
-0.003 -0.87
705,635
38.52M
US$ 13.140M
US$ 0.39
0.03 6.81
1.54M
32.58M
US$ 12.770M
US$ 2.43
0.17 7.52
618,485
5.23M
US$ 12.710M
US$ 0.61
0.00 0.00
0
19.72M
US$ 11.960M
C$ 0.05
0.00 0.00
13,000
227.04M
C$ 11.350M
US$ 1.19
-0.03 -2.46
160,390
8.88M
US$ 10.570M
US$ 0.95
0.00 0.00
128,761
10.89M
US$ 10.350M
US$ 3.86
-0.07 -1.66
39,244
2.61M
US$ 10.060M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
US$ 0.42
-0.0079 -1.85
311,127
21.93M
US$ 9.210M
US$ 0.59
0.0006 0.10
363,083
15.70M
US$ 9.180M
US$ 9.00
-0.30 -3.23
864,446
1.02M
US$ 9.180M
US$ 0.30
0.05 17.69
1.44M
29.57M
US$ 8.870M
US$ 2.98
0.03 1.02
23,427
2.82M
US$ 8.400M
US$ 7.56
0.23 3.14
270,034
1.08M
US$ 8.160M
US$ 3.00
-0.34 -10.18
112,543
2.54M
US$ 7.620M
US$ 1.66
-0.02 -1.19
46,492
4.58M
US$ 7.600M
US$ 0.10
0.00 0.00
0
73.90M
US$ 7.390M
C$ 0.07
0.005 7.69
14,142
101.29M
C$ 7.090M
C$ 0.07
-0.005 -6.67
28,500
100.43M
C$ 7.030M
US$ 1.57
-0.01 -0.63
196,447
4.17M
US$ 6.550M
US$ 0.76
-2.35 -75.56
167,775
8.30M
US$ 6.310M
US$ 1.11
-0.05 -4.31
145,854
5.64M
US$ 6.260M
US$ 2.39
0.00 0.00
0
2.39M
US$ 5.710M
US$ 6.49
0.24 3.84
12,551
796,950
US$ 5.170M
US$ 0.29
0.00 0.00
0
16.88M
US$ 4.900M
US$ 3.11
0.04 1.30
23,370
1.57M
US$ 4.880M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 0.74
0.06 8.16
77,646
5.85M
US$ 4.340M
US$ 2.31
-0.01 -0.43
20,700
1.86M
US$ 4.300M
US$ 0.04
0.00 0.00
11,400
96.71M
US$ 4.060M
C$ 0.07
0.02 40.00
865,280
56.81M
C$ 3.980M
US$ 2.13
0.02 0.95
145,544
1.80M
US$ 3.830M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 4.18
-0.03 -0.71
19,198
902,665
US$ 3.770M
US$ 4.74
0.13 2.82
35,129
752,755
US$ 3.570M
US$ 2.45
-0.05 -1.88
15,822
1.23M
US$ 3.020M
US$ 1.57
0.10 6.80
435,003
1.49M
US$ 2.340M
US$ 1.18
0.00 0.00
0
1.82M
US$ 2.140M
US$ 0.77
-0.02 -2.15
930,108
2.60M
US$ 2.010M
US$ 0.16
0.00 0.00
0
10.59M
US$ 1.690M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 2.68
0.15 5.93
204,108
519,000
US$ 1.390M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.25
0.00 0.00
0
5.24M
US$ 1.320M
US$ 0.08
0.00 0.00
0
10.62M
US$ 860K
US$ 0.03
0.00 0.00
0
25.29M
US$ 860K
C$ 0.08
0.00 0.00
0
4.82M
C$ 386K
US$ 0.73
0.03 4.29
900
427,401
US$ 312K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.006
0.0005 9.09
1,481
28.05M
US$ 168K
US$ 0.001
0.00 0.00
0
29.91M
US$ 30K
US$ 0.01
0.00 0.00
0
1.78M
US$ 21K
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
0.00 0.00
0
6.39M
US$ -
C$ 0.48
0.00 0.00
49,500
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


MBody AI and Check-Cap Enter into Definitive Merger Agreement

Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI (“MBody AI”) and Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger”). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous... Read more


Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis

Expanded indication provides patients with knee osteoarthritis the benefits of Embosphere’s consistent, predictable, and effective clinical results. SOUTH JORDAN, Utah, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that Embosphere® Microspheres are now indicated in the European Union for use in genicular artery embolisation (GAE) to treat patients with knee osteoarthritis... Read more


Intuitive Introduces Real-Time Surgical Insights for da Vinci 5

New Force Gauge, In-Console Video Replay, and Network CCM features designed for enhanced efficiency SUNNYVALE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the first in a series of new software capabilities for da Vinci 5, designed to enhance surgeon and hospital efficiency through the delivery of a range of real-time surgical... Read more


Prenetics Global Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End

1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward CHARLOTTE, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... Read more


FONAR Announces Financial Results for Fiscal 2025

Cash and Cash Equivalents was $56.3 million at June 30, 2025 and the previous fiscal year. Total Revenues - Net increased 1% to $104.4 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Income from Operations decreased 30% to $11.6 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Net Income decreased 24% to $10.7 million for the fiscal year ended June 30, 2025 versus the previous fiscal ye... Read more


HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 (“FQ1 2026”) and provided a business update highlighting continued progress. First Quarter and Recent Hi... Read more


Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025

Event Will Feature Global KOLs Sharing Their Perspectives on the Role of Adaptive Radiotherapy in Radiation Medicine MADISON, Wis., Sept. 11, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Monday, September 29, 2025, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California. The event will take place in person at... Read more


Modular Medical Announces Completion of Clinical Study of MODD1 Pump

Use of MODD1 on clinicians with Type 1 diabetes SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target the estimated $3 billion dollar adult "almost-pumpers" market with its user-friendly and affordable design, today announced the successful completion of a clinical study with the MODD1... Read more


Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period. Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period. Increased... Read more


Co-Diagnostics Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains

SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of the primers sets used in its Co-Primers®-based PCR tests for the detection of chikungunya virus (or "CHIKV"), showing a high homology against over 1,200 CHIKV sequences and confirming... Read more


Inspira Technologies Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance

RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase that will support its upcoming U.S. Food and Drug Administration (“FDA”) submission. These results represent a... Read more


Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth  ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm Insemination Prep Kit, designed to fully... Read more


Tempus AI Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

CHICAGO / Sep 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis. Tempus Pixel provides... Read more


Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening LabFlorida/SunDX will provide patients in assisted and independent living communities, as well as residential care facilities across 20 states access to Shield LabFlorida exclusively distributing Shield in senior centers in Florida PALO ALTO, Calif. / Sep 11, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq:... Read more


Masimo Announces Expansion of Strategic Partnership with Philips

Multi-Year Partnership Renewal with Broadened Focus Will Include Expedited Technology Adoption and Market-Based Strategic Development of Next-Generation Monitoring Solutions IRVINE, Calif. / Sep 11, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced a multi-year renewal and expansion of its strategic partnership with Royal Philips (NYSE: PHG, AEX: PHIA). Building on over two decades of collaboration, this significant partnership expansion is designed to accelerate... Read more


Charles River Laboratories Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

WILMINGTON, Mass. / Sep 11, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process for Children’s Hospital Los Angeles’... Read more


Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries... Read more


Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter study Results show that enVista Envy IOLs deliver excellent visual performance, good contrast sensitivity and a favorable dysphotopsia profile VAUGHAN, Ontario / Sep 11, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the... Read more


Teleflex: First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients

The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents WAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the enrollment of the first patient in the DUBSTENT DIABETES trial. The randomized, investigator-initiated clinical study will evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes... Read more


Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares,... Read more


Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA

Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and Discovery FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced, high-parameter solutions at two notable industry events later this month: the European Society for Clinical Cell Analysis (ESCCA) 2025 Conference... Read more


QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx Meningitis/Encephalitis (ME) Panel, sets standard with 16 targets for central nervous system infections and broadest coverage for fast and accurate diagnosis QIAstat-Dx panels offer unique advantages, including exclusive and medically valuable targets combined with a one-step workflow... Read more


GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

MENLO PARK, Calif., Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum on Wednesday, Sep. 24 at 8:00 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast... Read more


Sharps Technology and Pudgy Penguins Announce Strategic Partnership

NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Sharps Technology ("Sharps Technology" or the "Company") (NASDAQ: STSS), a leading publicly listed Solana treasury, and Pudgy Penguins, the globally recognized Web3 brand, today announced a strategic partnership to bring exposure and connectivity to the Solana digital asset treasury space. Pudgy Penguins has emerged as one of the most iconic and innovative brands in crypto—often called the internet's Mickey Mouse and Asia's... Read more


Danaher: Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio of neurodegenerative disease RUO... Read more


Tivic Health Systems Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

FREMONT, Calif. / Sep 10, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it has completed verification of its Entolimod™ cell line, the first step in establishing Current Good Manufacturing Practices (CGMP) in preparation for a Biologics License Application, or BLA. Cell line verification in recombinant protein production is required because it ensures the processes used to grow cells and... Read more


Spectral AI: DeepView® System highlighted at the European Burns Association Congress

DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the European Burns Association (EBA) conference, held from September 3rd – 6th in Berlin, Germany. The Company was featured in multiple presentations, highlighting its contributions... Read more


IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

RESEARCH TRIANGLE PARK, N.C. / Sep 10, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes.... Read more


Treace Medical Concepts Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting

PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting... Read more


Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Clinical Data on Benign Thyroid Nodule Ablation to be highlighted in presentation HAYWARD, Calif. / Sep 10, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the company will present clinical data on benign thyroid nodule ablation using nPulse™ Vybrance™ technology at the American Thyroid... Read more


Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection Offered as a laboratory-developed test at $689 Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites MADISON, Wis. / Sep 10, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available... Read more


Picard Medical Announces Appointment of Two New Members to its Board of Directors

Appointments strengthen Picard’s Board with proven expertise in capital markets and global MedTech leadership TUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the appointment of two new members that will serve on its Board of Directors,... Read more


Varex Imaging to Present at the Sidoti Small Cap Virtual Conference

SALT LAKE CITY / Sep 09, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the Sidoti Small Cap Virtual Conference. Management will be presenting on Wednesday, September 17, 2025 at 3:15pm ET. The webcast can be accessed here or on Varex’s website at www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which... Read more


Autonomix Medical Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress

Presentation to highlight findings from the first phase of the Company’s ongoing first-in-human proof-of-concept (PoC) clinical trial THE WOODLANDS, TX, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its technology and findings from the first phase of its first-in-human proof-of-concept study... Read more


VolitionRx Signs First Human Out Licensing Deal

HENDERSON, Nev., Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics. Full terms of the agreement are confidential. Commenting on the agreement, Mr. Gael Forterre, Chief Commercial... Read more


Tempus AI Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

Real-world evidence demonstrates PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) CHICAGO / Sep 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic... Read more


Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testing IBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwide IRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods® IBS Trigger Food Navigator, a comprehensive... Read more


Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology

Patents strengthen Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss. White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents expand the company's global i... Read more


bioAffinity Technologies - Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO / Sep 09, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product, CyPath® Lung, identified cancer... Read more


AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need MASON, Ohio / Sep 09, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT™ device, an innovative cryoablation technology used... Read more


Owlet Makes Premium Monitoring Possible for Every Family With New Dream Sight™ Video Monitor

Owlet’s new release creates the ultimate baby monitoring system for video, sleep, and medical-grade health tracking. LEHI, Utah / Sep 09, 2025 / Business Wire / Owlet, Inc. (NYSE: OWLT) (the “Company” or “Owlet”), the pioneer of smart infant monitoring, announces the launch of its new HD video baby monitor, Dream Sight™, and next-generation Dream Duo™. These products represent an important step for Owlet in the category, featuring advanced technology designed... Read more


Stryker Launches Incompass Total Ankle System at AOFAS 2025

Next-generation solution designed to simplify procedures and support long-term outcomes PORTAGE, Mich. / Sep 09, 2025 / Business Wire / Stryker (NYSE:SYK), a global leader in medical technologies, will launch its Incompass™ Total Ankle System at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Savannah, Georgia, September 10–13, 2025 (booth # 401). The FDA-cleared system is intended for patients with end-stage ankle arthritis and introduces... Read more


Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today... Read more


Shoulder Innovations Reports Second Quarter 2025 Financial Results

Company to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference Today at 8:30 a.m. ET GRAND RAPIDS, Mich., Sept. 9, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the second quarter ended June 30, 2025. Recent Business H... Read more


Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

XIIDRA significantly improved end-of-day eye dryness and discomfort and delivered longer comfortable contact lens wear time in as little as two weeks Continued use further improved discomfort VAUGHAN, Ontario / Sep 09, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study... Read more


Castle Biosciences: New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved...

In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelines recommend prompt intervention for LGD to prevent disease progression FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative... Read more


Picard Medical Announces Exercise of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering

TUCSON, Ariz., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that the underwriters of its previously announced initial public offering of common stock, par value $0.0001 per share (the “Common Stock”) have exercised their over-allotment option in full on September 5, 2025, resulting in the issuance of an additional 637,500 shares of Common Stock at a public offering price of $4.00 per... Read more


Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to grant the underwriters a 30-day option to purchase additional shares of common stock. Proceeds from the offering... Read more


CONMED Adds Kim Kelderman to its Board of Directors

LARGO, Fla. / Sep 09, 2025 / Business Wire / CONMED Corporation (NYSE: CNMD) today announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025. “My fellow directors and I are delighted to welcome Kim to the board,” said LaVerne Council, Chair of CONMED’s Board of Directors. “Kim brings extensive global leadership experience across life sciences businesses, with a strong track record in innovation and strategy. Kim’s skills and... Read more


Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

Veteran life sciences industry financing leader appointed as new Board member HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board’s Nominating and Governance Committee. “We are pleased to announce Steve as the newest member... Read more